Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | HPGDS | O60760 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456619 | 0.78 | — | — | |
| SCHEMBL7526154 | 0.78 | LMNA (0.42) | LMNACES2HPGDS | |
| SCHEMBL1074362 | 0.77 | — | — | |
| SCHEMBL43311 | 0.77 | EPHX1 (0.31) | — | |
| SCHEMBL1299313 | 0.75 | LMNA (0.44) | LMNACES2 | |
| SCHEMBL3145985 | 0.73 | — | — | |
| SCHEMBL844660 | 0.73 | — | — | |
| SCHEMBL3316886 | 0.72 | LMNA (0.45) | LMNACES2 | |
| SCHEMBL8502985 | 0.71 | LMNA (0.38) | LMNACES2 | |
| SCHEMBL21748209 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046658-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2021-06-29 | — | — | US | claimed |
| US-20200291018-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-17 | — | — | US | claimed |
| EP-3652174-A1 | TAM KINASE INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| WO-2019014513-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | WO | claimed |
| US-20220411383-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11046658-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200291018-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3652174-A1 | TAM KINASE INHIBITORS | Syros Pharmaceuticals, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019014513-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
| US-7846933-B2 | such as 1-(4-Fluorophenyl)-5-(pyridin-4-yl)-4-imidazolin-2-one, having excellent p38 MAP kinase inhibitory action, useful for the treatment of osteoarthritis, arthritis, ulcerative colitis, Crohn's disease, psoriasis, dermatitis, asthma, bronchitis, pneumonia, rhinitis, conjunctivitis or keratitis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | KUBO AKIRA | 2009-04-02 | — | — | US | disclosed |
| US-7473695-B2 | 4-imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-06 | — | — | US | disclosed |
| EP-1628968-A4 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1628968-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004094404-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2004-11-04 | — | — | WO | disclosed |
| US-20040204426-A1 | 4-Imidazolin-2-one compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046658-B2 | Aminopyrazine derivatives as PI3K-γ inhibitors | PIK3R5, PIK3CD, PIK3CG | LMNA 4191/4885CES2 4616/4885HPGDS 784/4885 |
| US-20200291018-A1 | TAM KINASE INHIBITORS | MAP3K1, PIK3CA, MAP3K5 | LMNA 3146/4885CES2 2539/4885HPGDS 855/4885 |
| US-20040204426-A1 | 4-Imidazolin-2-one compounds | NR3C1, NR3C2, SCN1B | LMNA 3562/4885CES2 2176/4885HPGDS 4370/4885 |
| US-20220411383-A1 | AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS | PIK3R5, PIK3CD, PIK3CG | LMNA 4073/4885CES2 4703/4885HPGDS 936/4885 |
| US-20090088422-A1 | 4-IMIDAZOLIN-2-ONE COMPOUNDS | OR10J3, NR4A3, NR3C2 | LMNA 4247/4885CES2 1768/4885HPGDS 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.